Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-GGGo
- Development stage
- Preclinical
- Lead developer
- D&D Pharmatech
- Modality
- Peptides
- Administration
- Oral
01
Overview
MET-GGGo is an investigational triple agonist peptide developed by D&D Pharmatech for the treatment of obesity, diabetes, and metabolic diseases. It simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This multi-receptor approach aims to leverage the synergistic effects of GLP-1 and GIP on insulin secretion and appetite suppression, combined with the energy expenditure-increasing properties of glucagon. MET-GGGo is part of D&D Pharmatech's oral peptide portfolio, utilizing their proprietary ORALINK platform to enable oral administration of peptide therapeutics.
02
Targets
Beyond the preview
Go deeper on MET-GGGo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-GGGo.